Visitors to The smarter E Europe, Europe’s Largest Alliance of Exhibitions for the Energy Industry, will find out how private consumers can become self-sufficient in electricity, heat and transport in a smart way and how this creates new business opportunities for installers and system providers. The smarter E Europe combines the four trade fairs Intersolar Europe, ees Europe, Power2Drive Europe and EM-Power Europe and takes place from June 19 to 21 at Messe München. Around 3,000 exhibitors and more than 115,000 visitors from all over the world are expected in 19 exhibition halls and on an outdoor area.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240528827105/en/ Solar Panel Power Cable
The smarter E Europe shows interplay of components. ©Solar Promotion GmbH
There are around 19.3 million residential buildings in Germany. More than half of these will need to be renovated and equipped with photovoltaics over the next 20 years. But residential buildings also play a central role in solar expansion throughout Europe. Everywhere, solar systems are being installed with storage systems, as this allows the solar power generated to be used as needed.
Increasing electrification in the transport and heating sectors
Solar power has been generated and stored to supply the home, but what else can it be used for? For the increasingly popular electric car. In the home system, battery electric vehicles as well as heat pumps can be charged and operated cost-effectively and climate-neutrally with the solar power. In Germany, 51 percent more heat pumps were sold last year than in 2022. With the adoption of the EU Heat Pump Action Plan, this development will continue dynamically. The combination of PV, a storage system, electric car and heat pump forms an effective network of electricity-generating, electricity-storing and electricity-consuming units.
An interplay of components and trade disciplines
The industry offers a wide range of components - from PV systems and intelligent wall boxes to smart meters and much more. However, successfully building a comprehensive energy system requires not only interaction between the individual components, but also smooth cooperation between the electrical trade, plumbing, heating and air conditioning technology (HVAC) and other trades.
Optimize self-consumption, relieve the grid
The electricity system requires a high degree of flexibility in order to be able to provide a renewable energy supply 24/7. Flexible small consumers with their own home energy systems can make a major contribution to keeping electricity generation and consumption in balance while optimizing their own consumption at low cost.
Dynamic electricity tariffs: Supply meets demand
Dynamic electricity tariffs are another way of better coordinating supply and demand. Consumers base their consumption on the current electricity prices, which change depending on supply and demand. From 2025, all electricity suppliers in Germany will be obliged to offer their customers a dynamic electricity tariff. Prerequisite for this is the installation of a smart meter.
"Accelerating Integrated Energy Solutions" - under this motto, The smarter E Europe, Europe's largest trade fair alliance for the energy industry, focuses on cross-industry solutions for a 24/7 renewable energy supply in the electricity, heating and transport sectors. The smarter E Europe combines four trade fairs and will take place from June 19-21, 2024 at Messe München.
Further information: www.TheSmarterE.de
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240528827105/en/
Solar Promotion GmbH Horst Dufner |Tel.: +49 7231 58598-0 |Fax: +49 7231 58598-28 dufner@solarpromotion.de Press contact: lack of resources at Panke GmbH Roberto Freiberger |Tel.: +49 163 8430 943 roberto.freiberger@immobilienlack.de Solar Promotion GmbH Peggy Zilay |Tel.: +49 7231 58598-240 zilay@solarpromotion.com
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
PMC Biogenix, the leading sustainable producer of specialty fatty amides and high-value biobased products, announces the construction and expansion of its new Armoslip® facility in Gyeongju, South Korea allowing for a production capacity increase of 50%. Construction will begin late 2024 with new supply available by mid-2026. “We are excited to announce plans to build a new facility in Gyeongju. This investment will allow us to significantly increase production capacity to meet growing customer demand for our Armoslip products,” said Debtosh Chakrabarti, President, PMC Group N.A., Inc. Adding, “This project solidifies our commitment as the industry leader, delivering products and solutions to our customers, as well as to the local Gyeongju community. We appreciate the continued support of the Gyeongju, South Korea local government, community, and our customers.” As part of PMC’s ongoing commitment of ensuring long-term sustainability and success of the Biogenix business world-wide, a c
The ALS Therapy Development Institute (ALS TDI), a nonprofit biotech dedicated to ending amyotrophic lateral sclerosis (ALS), has used mapping technology from Esri, the global leader in location intelligence, to develop the ALS Trial Navigator. The new tool is designed to simplify and streamline the process by which people with ALS and their caretakers learn about current ALS studies. With the ALS Trial Navigator users can now explore an interactive map to find locations where applicable clinical trials are taking place. They can also receive a customized map based on their preferences and status of their ALS. "ALS Trial Navigator helps people living with ALS, those that might face it in the future, and researchers looking to enroll trials by educating the community and providing information about current studies all around the world," said Dr. Nadia Sethi, ALS TDI's director of community engagement, who oversaw the Navigator's design and creation. Once a person is diagnosed with ALS,
Lifezone Metals Limited (NYSE: LZM) announces the results of voting by shareholders at its 2024 Annual General Meeting (the “AGM”) held today in the Isle of Man. The ordinary resolutions below were passed by shareholders, with voting results as follows: Ordinary Resolutions For % For Against % Against Abstain % Abstain To receive the Company’s accounts for the financial year ended December 31, 2023 60,456,134 100.00% 0 0.00% 264 0.00% To re-elect John Dowd as a Class I Director of the Company 60,375,930 99.87% 79,177 0.13% 1,291 0.00% To re-elect Govind Friedland as a Class I Director of the Company 59,713,208 98.77% 79,319 0.13% 663,871 1.10% To re-elect Ambassador Mwanaidi Maajar as a Class I Director of the Company 60,314,469 99.77% 81,886 0.14% 60,043 0.10% A total of 60,456,398 or 75.57% of Lifezone Metals Ordinary Shares outstanding were represented at the AGM. If you would like to sign up for Lifezone Metals news alerts, please register here. About Lifezone Metals At Lifezone Me
Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved FRUZAQLA (fruquintinib) as a monotherapy indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents, and who have progressed on or are intolerant to treatment with either trifluridine-tipiracil or regorafenib. The decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on April 25, 2024, and approval by the U.S. Food and Drug Administration (FDA) for adults with mCRC who have been previously treated with oxaliplatin- and irinotecan-based regimens on November 8, 2023.1,2 “People living with metastatic colorectal cancer face numerous difficulties, stemming both from their illness and the adverse effects of therapies. Given the complex nature of the d
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today presented new data from its Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). These updated data on 12 patients who received the full dose as a single infusion in Parts B and C of the trial are consistent with previously reported positive results in the VX-880 trial and reinforce the transformative potential of this therapy. At baseline, all patients in the study had undetectable fasting C-peptide (a marker of endogenous insulin secretion), a history of recurrent SHEs in the year prior to screening, and required an average of 39.3 (min, max; 19.8, 52.0) units of insulin per day. Following a single infusion of VX-880 at the full dose, all 12 patients demonstrated islet cell engraftment and glucose-responsive insulin production by Day 90. At the latest visi
Solar Panel Wire Connectors In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.